Keros will also stop work on a cardiovascular disease drug. Elsewhere, Stealth Biotherapeutics and Taysha Gene Therapies each ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

The funding was meant to help the U.S. prepare for pandemics triggered by avian flu strains, but now leaves the future of ...

After a three-year drought, the industry is questioning whether the window for medtech public offerings is open following a ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Weeks after shelving a TIGIT drug prospect, the biotech is seeking to sell off its assets and intellectual property in a bid ...

Commissioner Martin Makary and two of his deputies aim to meet with drugmaker CEOs to discuss how the agency can “modernize” ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

The agency recommends manufacturers update their vaccines to target the JN.1 strain. At the same time, HHS head Robert F.

The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause ...